-
-
-
-
-
-
-
CRISPR Therapeutics (CRSP) Reiterated at Market Outperform by Citizens
-
-
-
-
-
-
-
CRISPR Therapeutics (CRSP) PT Lowered to $80 at Citizens: Pipeline Not Valued
-
-
-
-
-
-
-
CRISPR Therapeutics (CRSP) Strength Said to be Tied to Unconfirmed M&A Chatter
-
-
-
-
-
-
-
Form SCHEDULE 13G/A CRISPR Therapeutics AG Filed by: ARK Investment Management LLC
-
-
-
-
-
-
-
H.C. Wainwright Reiterates Buy Rating on CRISPR Therapeutics (CRSP)
-
-
-
-
-
-
-
H.C. Wainwright Reiterates Buy Rating on CRISPR Therapeutics (CRSP)
-
-
-
-
-
-
-
William Blair Reiterates Outperform Rating on CRISPR Therapeutics (CRSP)
-
442,884 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

